Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Camphausen Website

Kevin A. Camphausen, M.D.

Selected Publications

1)  Ho J, Ondos J, Ning H, Smith S, Kreisl T, Iwamoto F, Sul J, Kim L, McNeil K, Krauze A, Shankavaram U, Fine HA, Camphausen K.
Chemoirradiation for glioblastoma multiforme: the national cancer institute experience.
PLoS ONE. 8: e70745, 2013.
2)  Hayman TJ, Kramp T, Kahn J, Jamal M, Camphausen K, Tofilon PJ.
Competitive but Not Allosteric mTOR Kinase Inhibition Enhances Tumor Cell Radiosensitivity.
Transl Oncol. 6: 355-62, 2013.
3)  Rath BH, Fair JM, Jamal M, Camphausen K, Tofilon PJ.
Astrocytes enhance the invasion potential of glioblastoma stem-like cells.
PLoS ONE. 8: e54752, 2013.
4)  Schlaff CD, Krauze A, Belard A, O Connell JJ, Camphausen KA.
Bringing the heavy: carbon ion therapy in the radiobiological and clinical context.
Radiat Oncol. 9: 88, 2014.
5)  Den RB, Kamrava M, Sheng Z, Werner-Wasik M, Dougherty E, Marinucchi M, Lawrence YR, Hegarty S, Hyslop T, Andrews DW, Glass J, Friedman DP, Green MR, Camphausen K, Dicker AP.
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Int. J. Radiat. Oncol. Biol. Phys. 85: 321-8, 2013.
6)  Citrin D, Camphausen KA.
Biomarkers for prostate cancer: who will benefit from local treatment, who harbors occult systemic disease and who needs treatment at all?.
Biomark Med. 7: 823-5, 2013.
7)  Citrin D, Hudak K, Camphausen KA.
Biomarkers to guide therapy or surveillance for prostate cancer.
Biomark Med. 7: 827-9, 2013.
8)  Saleh AD, Simone BA, Palazzo J, Savage JE, Sano Y, Dan T, Jin L, Champ CE, Zhao S, Lim M, Sotgia F, Camphausen K, Pestell RG, Mitchell JB, Lisanti MP, Simone NL.
Caloric restriction augments radiation efficacy in breast cancer.
Cell Cycle. 12: 1955-63, 2013.
9)  Sproull M, Avondoglio D, Kramp T, Shankavaram U, Camphausen K.
Correlation of Plasma FL Expression with Bone Marrow Irradiation Dose.
PLoS ONE. 8: e58558, 2013.
10)  Shankavaram U, Fliedner SM, Elkahloun AG, Barb JJ, Munson PJ, Huynh TT, Matro JC, Turkova H, Linehan WM, Timmers HJ, Tischler AS, Powers JF, de Krijger R, Baysal BE, Takacova M, Pastorekova S, Gius D, Lehnert H, Camphausen K, Pacak K.
Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas.
Neoplasia. 15: 435-47, 2013.
11)  Chung C, Jalali S, Foltz W, Burrell K, Wildgoose P, Lindsay P, Graves C, Camphausen K, Milosevic M, Jaffray D, Zadeh G, Ménard C.
Imaging biomarker dynamics in an intracranial murine glioma study of radiation and antiangiogenic therapy.
Int. J. Radiat. Oncol. Biol. Phys. 85: 805-12, 2013.
12)  Arscott WT, Tandle AT, Zhao S, Shabason JE, Gordon IK, Schlaff CD, Zhang G, Tofilon PJ, Camphausen KA.
Ionizing radiation and glioblastoma exosomes: implications in tumor biology and cell migration.
Transl Oncol. 6: 638-48, 2013.
13)  Krauze AV, Won M, Graves C, Corn BW, Muanza TM, Howard SP, Mahadevan A, Schultz CJ, Haas ML, Mehta MP, Camphausen KA.
Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM).
Biomark Res. 1: 29, 2013.
14)  Oh SY, Kwon HC, Kim SH, Lee S, Lee JH, Graves CA, Camphausen K, Kim HJ.
Prognostic Significance of Serum Levels of Vascular Endothelial Growth Factor and Insulin-Like Growth Factor-1 in Advanced Gastric Cancer Patients Treated with FOLFOX Chemotherapy.
Chemotherapy. 58: 426-434, 2013.
15)  Ho J, Turkbey B, Edgerly M, Alimchandani M, Quezado M, Camphausen K, Fojo T, Kaushal A.
Role of radiotherapy in adrenocortical carcinoma.
Cancer J. 19: 288-94, 2013.
16)  Hayman TJ, Wahba A, Rath BH, Bae H, Kramp T, Shankavaram U, Camphausen KA, Tofilon PJ.
The ATP-Competitive mTOR Inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells.
Clin. Cancer Res. 2013.
17)  Oh SY, Kwon HC, Kim SH, Lee S, Lee JH, Hwang JA, Hong SH, Graves CA, Camphausen K, Kim HJ, Lee YS.
The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer.
BMC Cancer. 13: 43, 2013.
18)  Prager AJ, Peng CR, Lita E, McNally D, Kaushal A, Sproull M, Compton K, Dahut WL, Figg WD, Citrin D, Camphausen KA.
Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer.
Biomark Med. 7: 831-41, 2013.
19)  Zibly Z, Schlaff CD, Gordon I, Munasinghe J, Camphausen KA.
A novel rodent model of spinal metastasis and spinal cord compression.
BMC Neurosci. 13: 137, 2012.
20)  Portal-Nuñez S, Shankavaram UT, Rao M, Datrice N, Atay S, Aparicio M, Camphausen KA, Fernández-Salguero PM, Chang H, Lin P, Schrump DS, Garantziotis S, Cuttitta F, Zudaire E.
Aryl hydrocarbon receptor-induced adrenomedullin mediates cigarette smoke carcinogenicity in humans and mice.
Cancer Res. 72: 5790-800, 2012.
21)  Song S, Cho N, Iordachita I, Guion P, Fichtinger G, Kaushal A, Camphausen K, Whitcomb L.
Biopsy Needle Artifact Localization in MRI-guided Robotic Transrectal Prostate Intervention.
IEEE Trans Biomed Eng. [Epub ahead of print], 2012.
22)  Kramp TR, Camphausen K.
Combination radiotherapy in an orthotopic mouse brain tumor model.
J Vis Exp. e3397, 2012.
23)  Shankavaram UT, Bredel M, Burgan WE, Carter D, Tofilon P, Camphausen K.
Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma.
J Cell Mol Med. 16: 545-54, 2012.
24)  Fitzgerald DP, Subramanian P, Deshpande M, Graves C, Gordon I, Qian Y, Snitkovsky Y, Liewehr DJ, Steinberg SM, Paltán-Ortiz JD, Herman MM, Camphausen K, Palmieri D, Becerra SP, Steeg PS.
Opposing effects of pigment epithelium-derived factor on breast cancer cell versus neuronal survival: implication for brain metastasis and metastasis-induced brain damage.
Cancer Res. 72: 144-53, 2012.
25)  Kil WJ, Tofilon PJ, Camphausen K.
Post-radiation increase in VEGF enhances glioma cell motility in vitro.
Radiat Oncol. 7: 25, 2012.
26)  Kahn J, Tofilon PJ, Camphausen K.
Preclinical models in radiation oncology.
Radiat Oncol. 7: 223, 2012.
27)  Gordon IK, Graves C, Kil WJ, Kramp T, Tofilon P, Camphausen K.
Radiosensitization by the novel DNA intercalating agent vosaroxin.
Radiat Oncol. 7: 26, 2012.
28)  Ko C, Kaushal A, Hammoud DA, Steffen-Smith EA, Bent R, Citrin D, Camphausen K, Warren KE.
Role of Early Postradiation Magnetic Resonance Imaging Scans in Children with Diffuse Intrinsic Pontine Glioma.
Int J Radiat Oncol Biol Phys. [Epub ahead of print], 2012.
29)  Johnson S, Issac B, Zhao S, Bisht M, Celiku O, Tofilon P, Camphausen K, Shankavaram U.
StRAP: an integrated resource for profiling high-throughput cancer genomic data from stress response studies.
PLoS ONE. 7: e51693, 2012.
30)  Jamal M, Rath BH, Tsang PS, Camphausen K, Tofilon PJ.
The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells.
Neoplasia. 14: 150-8, 2012.
31)  Hayman TJ, Williams ES, Jamal M, Shankavaram UT, Camphausen K, Tofilon PJ.
Translation Initiation Factor eIF4E Is a Target for Tumor Cell Radiosensitization.
Cancer Res. 72: 2362-72, 2012.
32)  Wuthrick EJ, Kamrava M, Curran WJ, Werner-Wasik M, Camphausen KA, Hyslop T, Axelrod R, Andrews DW, Glass J, Machtay M, Dicker AP.
A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies.
Cancer. 117: 5548-59, 2011.
33)  Arscott WT, Camphausen KA.
Analysis of urinary exosomes to identify new markers of non-small-cell lung cancer.
Biomark Med. 5: 822, 2011.
34)  Steeg PS, Camphausen KA, Smith QR.
Brain metastases as preventive and therapeutic targets.
Nat. Rev. Cancer. 11: 352-63, 2011.
35)  Arscott WT, Camphausen KA.
EGFR isoforms in exosomes as a novel method for biomarker discovery in pancreatic cancer.
Biomark Med. 5: 821, 2011.
36)  Urick ME, Chung EJ, Shield WP, Gerber N, White A, Sowers A, Thetford A, Camphausen K, Mitchell J, Citrin DE.
Enhancement of 5-Fluorouracil-induced In Vitro and In Vivo Radiosensitization with MEK Inhibition.
Clin Cancer Res. 17: 5038-5047, 2011.
37)  Arscott WT, Camphausen KA.
Exosome characterization from ascitic fluid holds promise for identifying markers of colorectal cancer.
Biomark Med. 5: 821-2, 2011.
38)  Simone CB, Lonser RR, Ondos J, Oldfield EH, Camphausen K, Simone NL.
Infratentorial craniospinal irradiation for von Hippel-Lindau: a retrospective study supporting a new treatment for patients with CNS hemangioblastomas.
Neuro-Oncol. 13: 1030-6, 2011.
39)  de Groot JF, Piao Y, Tran HT, Gilbert MR, Wu H, Liu J, Bekele BN, Cloughesy T, Mehta MP, Robins HI, Lassman AB, Deangelis LM, Camphausen K, Chen A, Yung WK, Prados MD, Wen PY, Heymach JV.
Myeloid Biomarkers Associated with Glioblastoma Response to Anti-Vascular Endothelial Growth Factor Therapy with Aflibercept.
Clin Cancer Res. 17: 4872-81, 2011.
40)  Park D, Don AS, Massamiri T, Karwa A, Warner B, MacDonald J, Hemenway C, Naik A, Kuan KT, Dilda PJ, Wong JW, Camphausen K, Chinen L, Dyszlewski M, Hogg PJ.
Noninvasive imaging of cell death using an Hsp90 ligand.
J. Am. Chem. Soc. 133: 2832-5, 2011.
41)  Housri N, Ning H, Ondos J, Choyke P, Camphausen K, Citrin D, Arora B, Shankavaram U, Kaushal A.
Parameters favorable to intraprostatic radiation dose escalation in men with localized prostate cancer.
Int. J. Radiat. Oncol. Biol. Phys. 80: 614-20, 2011.
42)  Shabason JE, Camphausen K.
Cancer stem cells as a prognostic indicator for glioblastoma multiforme.
Biomark Med. 4: 127-8, 2010.
43)  Stall B, Zach L, Ning H, Ondos J, Arora B, Shankavaram U, Miller RW, Citrin D, Camphausen K.
Comparison of T2 and FLAIR imaging for target delineation in high grade gliomas.
Radiat Oncol. 5: 5, 2010.
44)  Korde LA, Lusa L, McShane L, Lebowitz PF, Lukes L, Camphausen K, Parker JS, Swain SM, Hunter K, Zujewski JA.
Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.
Breast Cancer Res. Treat. 119: 685-99, 2010.
45)  Shabason JE, Tofilon PJ, Camphausen K.
HDAC inhibitors in cancer care.
Oncology. 24: 180-5, 2010.
46)  Asthagiri AR, Mehta GU, Zach L, Li X, Butman JA, Camphausen KA, Lonser RR.
Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel-Lindau disease.
Neuro-Oncol. 12: 80-6, 2010.
47)  Buchanan IM, Scott T, Tandle AT, Burgan WE, Burgess TL, Tofilon PJ, Camphausen K.
Radiosensitization of glioma cells by modulation of Met signaling with the hepatocyte growth factor neutralizing antibody, AMG102.
J Cell Mol Med. 15: 1999-2006, 2010.
48)  Zach L, Stall B, Ning H, Ondos J, Arora B, Uma S, Miller RW, Citrin D, Camphausen K.
A dosimetric comparison of four treatment planning methods for high grade glioma.
Radiat Oncol. 4: 45, 2009.
49)  Li G, Xie H, Ning H, Lu W, Low D, Citrin D, Kaushal A, Zach L, Camphausen K, Miller RW.
A novel analytical approach to the prediction of respiratory diaphragm motion based on external torso volume change.
Phys Med Biol. 54: 4113-30, 2009.
50)  McCord AM, Jamal M, Williams ES, Camphausen K, Tofilon PJ.
CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines.
Clin. Cancer Res. 15: 5145-53, 2009.
51)  Kamrava M, Bernstein MB, Camphausen K, Hodge JW.
Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination?.
Mol Biosyst. 5: 1262-70, 2009.
52)  Avondoglio D, Scott T, Kil WJ, Sproull M, Tofilon PJ, Camphausen K.
High throughput evaluation of gamma-H2AX.
Radiat Oncol. 4: 31, 2009.
53)  De Siervi A, De Luca P, Moiola C, Gueron G, Tongbai R, Chandramouli GV, Haggerty C, Dzekunova I, Petersen D, Kawasaki E, Kil WJ, Camphausen K, Longo D, Gardner K.
Identification of new Rel/NFkappaB regulatory networks by focused genome location analysis.
Cell Cycle. 8: 2093-100, 2009.
54)  Russo AL, Kwon HC, Burgan WE, Carter D, Beam K, Weizheng X, Zhang J, Slusher BS, Chakravarti A, Tofilon PJ, Camphausen K.
In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
Clin. Cancer Res. 15: 607-12, 2009.
55)  Chung EJ, Brown AP, Asano H, Mandler M, Burgan WE, Carter D, Camphausen K, Citrin D.
In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase.
Clin. Cancer Res. 15: 3050-7, 2009.
56)  Tofilon PJ, Camphausen K.
Molecular targets for tumor radiosensitization.
Chem. Rev. 109: 2974-88, 2009.
57)  Morgan NY, Kramer-Marek G, Smith PD, Camphausen K, Capala J.
Nanoscintillator conjugates as photodynamic therapy-based radiosensitizers: calculation of required physical parameters.
Radiat. Res. 171: 236-44, 2009.
58)  Rodríguez D, Cheung MC, Housri N, Quinones-Hinojosa A, Camphausen K, Koniaris LG.
Outcomes of Malignant CNS Ependymomas: An Examination of 2408 Cases Through the Surveillance, Epidemiology, and End Results (SEER) Database (1973-2005).
J. Surg. Res. 2009.
59)  Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA.
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
J. Clin. Oncol. 27: 740-5, 2009.
60)  McCord AM, Jamal M, Shankavaram UT, Shankavarum UT, Lang FF, Camphausen K, Tofilon PJ.
Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro.
Mol. Cancer Res. 7: 489-97, 2009.
61)  Li G, Arora NC, Xie H, Ning H, Lu W, Low D, Citrin D, Kaushal A, Zach L, Camphausen K, Miller RW.
Quantitative prediction of respiratory tidal volume based on the external torso volume change: a potential volumetric surrogate.
Phys Med Biol. 54: 1963-78, 2009.
62)  Kurshan N, Citrin DE, Camphausen KA.
Research highlights.
Biomark Med. 3: 17-9, 2009.
63)  Camphausen K.
Seminars in Radiation Oncology. Introduction.
Semin Radiat Oncol. 19: 141, 2009.
64)  Amyot F, Small A, Boukari H, Camphausen K, Gandjbakhche A.
Topology of the heterogeneous nature of the extracellular matrix on stochastic modeling of tumor-induced angiogenesis.
Microvasc. Res. 77: 87-95, 2009.
65)  Russo AL, Jedlicka K, Wernick M, McNally D, Kirk M, Sproull M, Smith S, Shankavaram U, Kaushal A, Figg WD, Dahut W, Citrin D, Bottaro DP, Albert PS, Tofilon PJ, Camphausen K.
Urine analysis and protein networking identify met as a marker of metastatic prostate cancer.
Clin. Cancer Res. 15: 4292-8, 2009.
66)  Baschnagel A, Russo A, Burgan WE, Carter D, Beam K, Palmieri D, Steeg PS, Tofilon P, Camphausen K.
Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts.
Mol. Cancer Ther. 8: 1589-95, 2009.
67)  Palmieri D, Lockman PR, Thomas FC, Hua E, Herring J, Hargrave E, Johnson M, Flores N, Qian Y, Vega-Valle E, Taskar KS, Rudraraju V, Mittapalli RK, Gaasch JA, Bohn KA, Thorsheim HR, Liewehr DJ, Davis S, Reilly JF, Walker R, Bronder JL, Feigenbaum L, Steinberg SM, Camphausen K, Meltzer PS, Richon VM, Smith QR, Steeg PS.
Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks.
Clin. Cancer Res. 15: 6148-57, 2009.
68)  Citrin D, Camphausen K.
Advancement of antiangiogenic and vascular disrupting agents combined with radiation.
Cancer Treat. Res. 139: 153-71, 2008.
69)  Li G, Citrin D, Camphausen K, Mueller B, Burman C, Mychalczak B, Miller RW, Song Y.
Advances in 4D medical imaging and 4D radiation therapy.
Technol. Cancer Res. Treat. 7: 67-81, 2008.
70)  Brown AP, Citrin DE, Camphausen KA.
Clinical biomarkers of angiogenesis inhibition.
Cancer Metastasis Rev. Epub ahead of print, 2008.
71)  Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, Tofilon PJ, Camphausen K.
In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide.
Clin. Cancer Res. 14: 931-8, 2008.
72)  Simone NL, Ménard C, Soule BP, Albert PS, Guion P, Smith S, Godette D, Crouse NS, Sciuto LC, Cooley-Zgela T, Camphausen K, Coleman CN, Singh AK.
Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score.
Int. J. Radiat. Oncol. Biol. Phys. 70: 90-5, 2008.
73)  Baschnagel A, Wolters PL, Camphausen K.
Neuropsychological testing and biomarkers in the management of brain metastases.
Radiat Oncol. 3: 26, 2008.
74)  Brown AP, Wendler DS, Camphausen KA, Miller FG, Citrin D.
Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerations.
J. Clin. Oncol. 26: 3987-94, 2008.
75)  Hayward RM, Kirk MJ, Sproull M, Scott T, Smith S, Cooley-Zgela T, Crouse NS, Citrin DE, Camphausen K.
Post-collection, pre-measurement variables affecting VEGF levels in urine biospecimens.
J. Cell. Mol. Med. 12: 343-50, 2008.
76)  Chinnaiyan P, Cerna D, Burgan WE, Beam K, Williams ES, Camphausen K, Tofilon PJ.
Postradiation sensitization of the histone deacetylase inhibitor valproic acid.
Clin. Cancer Res. 14: 5410-5, 2008.
77)  Kumaraswamy S, Chinnaiyan P, Shankavaram UT, Lü X, Camphausen K, Tofilon PJ.
Radiation-induced gene translation profiles reveal tumor type and cancer-specific components.
Cancer Res. 68: 3819-26, 2008.
78)  Chakraborty M, Wansley EK, Carrasquillo JA, Yu S, Paik CH, Camphausen K, Becker MD, Goeckeler WF, Schlom J, Hodge JW.
The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.
Clin. Cancer Res. 14: 4241-9, 2008.
79)  Chakraborty M, Gelbard A, Carrasquillo JA, Yu S, Mamede M, Paik CH, Camphausen K, Schlom J, Hodge JW.
Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects.
Cancer Immunol. Immunother. 57: 1173-83, 2008.
80)  Camphausen K, Tofilon PJ.
Inhibition of histone deacetylation: a strategy for tumor radiosensitization.
J. Clin. Oncol. 25: 4051-6, 2007.
81)  Camphausen K, Tofilon PJ.
Inhibition of Hsp90: a multitarget approach to radiosensitization.
Clin. Cancer Res. 13: 4326-30, 2007.
82)  Seggewiss R, Lore K, Guenaga FJ, Pittaluga S, Mattapallil J, Chow CK, Koup RA, Camphausen K, Nason MC, Meier-Schellersheim M, Donahue RE, Blazar BR, Dunbar CE, Douek DC.
Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques.
Blood. 110: 441-9, 2007.
83)  Kirk MJ, Hayward RM, Sproull M, Scott T, Smith S, Cooley-Zgela T, Crouse NS, Citrin DE, Camphausen K.
Non-patient related variables affecting levels of vascular endothelial growth factor in urine biospecimens.
J. Cell. Mol. Med. 2007.
84)  Simone NL, Soule BP, Gerber L, Augustine E, Smith S, Altemus RM, Mitchell JB, Camphausen KA.
Oral Pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study.
Radiat Oncol. 2: 19, 2007.
85)  Sharp HJ, Wansley EK, Garnett CT, Chakraborty M, Camphausen K, Schlom J, Hodge JW.
Synergistic antitumor activity of immune strategies combined with radiation.
Front. Biosci. 12: 4900-10, 2007.
86)  Rapkiewicz A, Espina V, Zujewski JA, Lebowitz PF, Filie A, Wulfkuhle J, Camphausen K, Petricoin EF, Liotta LA, Abati A.
The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology.
Cancer. 111: 173-84, 2007.
87)  Brown MW, Ning H, Arora B, Albert PS, Poggi M, Camphausen K, Citrin D.
A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma.
Int. J. Radiat. Oncol. Biol. Phys. 65: 274-83, 2006.
88)  Ahlers CM, Camphausen K, Citrin D, Arlen PM, Gulley JL.
A pilot trial of a carcinoembryonic antigen/ TRICOM-based vaccine and radiation to liver metastases in patients with carcinoembryonic antigen-positive solid tumors.
Clin Colorectal Cancer. 6: 72-5, 2006.
89)  Beecken WC, Engl T, Ringel EM, Camphausen K, Michaelis M, Jonas D, Folkman J, Shing Y, Blaheta RA.
An endogenous inhibitor of angiogenesis derived from a transitional cell carcinoma: cipped beta2-glycoprotein-I.
Ann Surg Oncol. 13: 1241-51, 2006.
90)  Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koeppen H, Sherman M, Zujewski J, Camphausen K, Chen H, Swain SM.
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.
J. Clin. Oncol. 24: 769-77, 2006.
91)  Beecken W, Engl T, Engels K, Blumenberg C, Oppermann E, Camphausen K, Shing Y, Reinecke G, Jonas D, Blaheta R.
Clinical relevance of maspin expression in bladder cancer.
World J Urol. 24: 338-44, 2006.
Full Text Article. [Journal]
92)  Citrin D, Menard C, Camphausen K.
Combining radiotherapy and angiogenesis inhibitors: clinical trial design.
Int. J. Radiat. Oncol. Biol. Phys. 64: 15-25, 2006.
93)  Menard C, Johann D, Lowenthal M, Muanza T, Sproull M, Ross S, Gulley J, Petricoin E, Coleman CN, Whiteley G, Liotta L, Camphausen K.
Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis.
Cancer Res. 66: 1844-50, 2006.
94)  Singh AK, Guion P, Susil RC, Citrin DE, Ning H, Miller RW, Ullman K, Smith S, Crouse NS, Godette DJ, Stall BR, Coleman CN, Camphausen K, Menard C.
Early observed transient prostate-specific antigen elevations on a pilot study of external beam radiation therapy and fractionated MRI guided High Dose Rate brachytherapy boost.
Radiat Oncol. 1: 28, 2006.
Full Text Article. [Journal]
95)  Bix G, Castello R, Burrows M, Zoeller JJ, Weech M, Iozzo RA, Cardi C, Thakur ML, Barker CA, Camphausen K, Iozzo RV.
Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism.
J. Natl. Cancer Inst. 98: 1634-46, 2006.
96)  Cerna D, Camphausen K, Tofilon PJ.
Histone deacetylation as a target for radiosensitization.
Curr. Top. Dev. Biol. 73: 173-204, 2006.
97)  Barker CA, Burgan WE, Carter DJ, Cerna D, Gius D, Hollingshead MG, Camphausen K, Tofilon PJ.
In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone).
Clin Cancer Res. 12: 2912-8, 2006.
98)  de la Pena L, Burgan WE, Carter DJ, Hollingshead MG, Satyamitra M, Camphausen K, Tofilon PJ.
Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells.
Mol. Cancer Ther. 5: 1504-10, 2006.
99)  Dote H, Burgan WE, Camphausen K, Tofilon PJ.
Inhibition of hsp90 compromises the DNA damage response to radiation.
Cancer Res. 66: 9211-20, 2006.
100)  Ullman KL, Ning H, Susil RC, Ayele A, Jocelyn L, Havelos J, Guion P, Xie H, Li G, Arora BC, Cannon A, Miller RW, Norman Coleman C, Camphausen K, Menard C.
Intra- and inter-radiation therapist reproducibility of daily isocenter verification using prostatic fiducial markers.
Radiat Oncol. 2006. 1: 2, 2006.
101)  Singh AK, Menard C, Guion P, Simone NL, Smith S, Crouse NS, Godette DJ, Cooley-Zgela T, Sciuto LC, Coleman J, Pinto P, Albert PS, Camphausen K, Coleman CN.
Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: A pilot study.
Clin Cancer Res. 65: 1008-13, 2006.
Full Text Article. [Journal]
102)  Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, K Wansley E, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P, Neefjes JJ.
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.
J. Exp. Med. 203: 1259-71, 2006.
103)  Lu X, de la Pena L, Barker C, Camphausen K, Tofilon PJ.
Radiation-induced changes in gene expression involve recruitment of existing messenger RNAs to and away from polysomes.
Cancer Res. 66: 1052-61, 2006.
104)  Susil RC, Menard C, Krieger A, Coleman JA, Camphausen K, Choyke P, Fichtinger G, Whitcomb LL, Coleman CN, Atalar E.
Transrectal prostate biopsy and fiducial marker placement in a standard 1.5T magnetic resonance imaging scanner.
J. Urol. 175: 113-20, 2006.
105)  Hassan R, Williams-Gould J, Steinberg SM, Liewehr DJ, Yokokawa J, Tsang KY, Surawski RJ, Scott T, Camphausen K.
Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts.
Clin Cancer Res. 12: 4983-8, 2006.
106)  Belka C, Camphausen KA.
Why radiation oncology?.
Radiat Oncol. 1: 1, 2006.
107)  Li G, Xie H, Ning H, Capala J, Arora BC, Coleman CN, Camphausen K, Miller RW.
A novel 3D volumetric voxel registration technique for volume-view-guided image registration of multiple imaging modalities.
Int. J. Radiat. Oncol. Biol. Phys. 63: 261-73, 2005.
108)  Menard C, Susil RC, Choyke P, Coleman J, Grubb R, Gharib A, Krieger A, Guion P, Thomasson D, Ullman K, Gupta S, Espina V, Liotta L, Petricoin E, Fitchtinger G, Whitcomb LL, Atalar E, Coleman CN, Camphausen K.
An interventional magnetic resonance imaging technique for the molecular characterization of intraprostatic dynamic contrast enhancement.
Clin. Cancer Res. 4: 63-6, 2005.
109)  Haas NA, Kulasekaran K, Camphausen C.
Beneficial hemodynamic response of transthoracic cardiac pacing in a 2 kg preterm neonate.
Intensive Care Med. 31: 877-9, 2005.
110)  Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang K, Yokokawa J, Hodge JW, Menard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W.
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Clin Cancer Res. 11: 3353-62, 2005.
111)  Muanza TM, Albert PS, Smith S, Godette D, Crouse NS, Cooley-Zgela T, Sciuto L, Camphausen K, Coleman CN, Menard C.
Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy.
Int. J. Radiat. Oncol. Biol. Phys. 62: 1316-21, 2005.
112)  Brooks JP, Danforth DN, Albert P, Sciuto LC, Smith SL, Camphausen KA, Poggi MM.
Early ipsilateral breast tumor recurrences after breast conservation affect survival: An analysis of the National Cancer Institute randomized trial.
Int J Radiat Oncol Biol Phys. 62: 785-9, 2005.
113)  Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, Hollingshead MG, Camphausen K, Tofilon PJ.
Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine.
Clin. Cancer Res. 11: 4571-9, 2005.
114)  Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, Fine H, Tofilon PJ.
Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid.
Int J Cancer. 114: 380-6, 2005.
115)  Dote H, Cerna D, Burgan WE, Camphausen K, Tofilon PJ.
ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition.
Cancer Res. 65: 6967-75, 2005.
116)  Camphausen K, Citrin D, Krishna MC, Mitchell JB.
Implications for tumor control during protection of normal tissues with antioxidants.
J. Clin. Oncol. 23: 5455-7, 2005.
117)  Camphausen K, Purow B, Sproull M, Scott T, Ozawa T, Deen DF, Tofilon PJ.
Influence of in vivo growth on human glioma cell line gene expression: Convergent profiles under orthotopic conditions.
Proc Natl Acad Sci U S A. 102: 8287-92, 2005.
Full Text Article. [Journal]
118)  Citrin D, Ning H, Guion P, Li G, Susil RC, Miller RW, Lessard E, Pouliot J, Huchen X, Capala J, Coleman CN, Camphausen K, Menard C.
Inverse treatment planning based on MRI for HDR prostate brachytherapy.
Int J Radiat Oncol Biol Phys. 61: 1267-75, 2005.
119)  Camphausen K, Purow B, Sproull M, Scott T, Ozawa T, Deen DF, Tofilon PJ.
Orthotopic growth of human glioma cells quantitatively and qualitatively influences radiation-induced changes in gene expression.
Cancer Res. 65: 10389-93, 2005.
120)  Kudo-Saito C, Schlom J, Camphausen K, Coleman CN, Hodge JW.
The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Int. J. Radiat. Oncol. Biol. Phys. 11: 4533-44, 2005.
121)  Beecken WD, Engl T, Blaheta R, Bentas W, Achilles EG, Jonas D, Shing Y, Camphausen K.
Angiogenesis inhibition by angiostatin, endostatin and TNP-470 prevents cyclophosphamide induced cystitis.
Angiogenesis. 7: 69-73, 2004.
122)  Camphausen K, Tofilon PJ.
Combining radiation and molecular targeting in cancer therapy.
Cancer Biol Ther. 3: 247-50, 2004.
123)  Camphausen K, Burgan W, Cerra M, Oswald KA, Trepel JB, Lee MJ, Tofilon PJ.
Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.
Cancer Res. 64: 316-21, 2004.
124)  Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, Oswald KA, Hollingshead MG, Camphausen K, Tofilon PJ.
Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
Clin Cancer Res. 10: 8077-84, 2004.
125)  Camphausen K, Scott T, Sproull M, Tofilon PJ.
Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation.
Clin Cancer Res. 10: 6066-71, 2004.
126)  Camphausen K, Sproull M, Tantama S, Venditto V, Sankineni S, Scott T, Brechbiel MW.
Evaluation of chelating agents as anti-angiogenic therapy through copper chelation.
Bioorg Med Chem. 12: 5133-40, 2004.
127)  Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW.
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.
Cancer Res. 64: 4328-37, 2004.
128)  Camphausen K, Brady KJ, Burgan WE, Cerra MA, Russell JS, Bull EE, Tofilon PJ.
Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci.
Mol Cancer Ther. 3: 409-16, 2004.
129)  Citrin D, Lee AK, Scott T, Sproull M, Menard C, Tofilon PJ, Camphausen K.
In vivo tumor imaging in mice with near-infrared labeled endostatin.
Mol Cancer Ther. 3: 481-8, 2004.
130)  Citrin D, Scott T, Sproull M, Menard C, Tofilon PJ, Camphausen K.
In vivo tumor imaging using a near-infrared-labeled endostatin molecule.
Int J Radiat Oncol Biol Phys. 58: 536-41, 2004.
131)  Camphausen K, Menard C, Sproull M, Goley E, Basu S, Coleman CN.
Isoprostane levels in the urine of patients with prostate cancer receiving radiotherapy are not elevated.
Int J Radiat Oncol Biol Phys. 58: 1536-9, 2004.
132)  Goley EM, Anderson SJ, Menard C, Chuang E, Lu X, Tofilon PJ, Camphausen K.
Microarray analysis in clinical oncology: pre-clinical optimization using needle core biopsies from xenograft tumors.
BMC Cancer. 4: 20, 2004.
133)  Menard C, Susil RC, Choyke P, Gustafson GS, Kammerer W, Ning H, Miller RW, Ullman KL, Sears Crouse N, Smith S, Lessard E, Pouliot J, Wright V, McVeigh E, Coleman CN, Camphausen K.
MRI-guided HDR prostate brachytherapy in standard 1.5T scanner.
Int J Radiat Oncol Biol Phys. 59: 1414-23, 2004.
134)  Citrin D, Camphausen K.
Optical imaging of mice in oncologic research.
Expert Rev Anticancer Ther. 4: 857-64, 2004.
135)  Green CE, Pearson DN, Camphausen RT, Staunton DE, Simon SI.
Shear-dependent capping of L-selectin and P-selectin glycoprotein ligand 1 by E-selectin signals activation of high-avidity beta2-integrin on neutrophils.
J Immunol. 172: 7780-90, 2004.
136)  Susil RC, Camphausen K, Choyke P, McVeigh ER, Gustafson GS, Ning H, Miller RW, Atalar E, Coleman CN, Menard C.
System for prostate brachytherapy and biopsy in a standard 1.5 T MRI scanner.
Magn Reson Med. 52: 683-7, 2004.
137)  Dertinger SD, Camphausen K, Macgregor JT, Bishop ME, Torous DK, Avlasevich S, Cairns S, Tometsko CR, Menard C, Muanza T, Chen Y, Miller RK, Cederbrant K, Sandelin K, Pontén I, Bolcsfoldi G.
Three-color labeling method for flow cytometric measurement of cytogenetic damage in rodent and human blood.
Environ Mol Mutagen. 44: 427-35, 2004.
138)  Lu X, Burgan WE, Cerra MA, Chuang EY, Tsai M, Tofilon PJ, Camphausen K.
Transcriptional signature of flavopiridol-induced tumor cell death.
Mol Cancer Ther. 3: 861-72, 2004.
139)  Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, Figg WD, Albert PS, Menard C, Camphausen K.
Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy.
J Clin Oncol. 22: 499-506, 2004.
140)  Chan LW, Camphausen K.
Angiogenic tumor markers, antiangiogenic agents and radiation therapy.
Expert Rev Anticancer Ther. 3: 357-66, 2003.
141)  Sproull M, Brechbiel M, Camphausen K.
Antiangiogenic therapy through copper chelation.
Expert Opin Ther Targets. 7: 405-9, 2003.
142)  Menard C, Camphausen K, Muanza T, Sears-Crouse N, Smith S, Ben-Josef E, Coleman CN.
Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results.
Semin Oncol. 30: 63-7, 2003.
143)  Colevas AD, Brown JM, Hahn S, Mitchell J, Camphausen K, Coleman CN, Radiation Modifier Working Group of the National Cancer Institute .
Development of investigational radiation modifiers.
J Natl Cancer Inst. 95: 646-51, 2003.
144)  Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ.
Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: a multitarget approach to radiosensitization.
Clinical Cancer Research. 9: 3749-3755, 2003.
145)  Camphausen K, Sproull M, Tantama S, Sankineni S, Scott T, Menard C, Coleman CN, Brechbiel MW.
Evaluation of copper chelation agents as anti-angiogenic therapy.
Bioorg Med Chem. 11: 4287-93, 2003.
146)  Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA, Camphausen K, Tofilon PJ.
Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity.
Cancer Res. 63: 7377-83, 2003.
147)  Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW.
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy.
J Immunol. 170: 6338-47, 2003.
148)  Ergun A, Camphausen K, Wein LM.
Optimal scheduling of radiotherapy and angiogenic inhibitors.
Bull Math Biol. 65: 407-24, 2003.
149)  Camphausen K, Moses MA, Menard C, Sproull M, Beecken W, Folkman J, O'Reilly MS.
Radiation abscopal antitumor effect is mediated through p53.
Cancer Res. 63: 1990-3, 2003.
150)  Camphausen K, Menard C.
Angiogenesis inhibitors and radiotherapy of primary tumours.
Expert Opin Biol Ther. 2: 477-81, 2002.
151)  Camphausen K.
Portrait of an editorial board member: judah folkman: the father of modern angiogenesis.
Cell Cycle. 1: 296-7, 2002.
152)  Coleman CN, Mitchell JB, Camphausen K.
Tumor hypoxia: chicken, egg, or a piece of the farm.
J Clin Oncol. 20: 610-5, 2002.
153)  Folkman J, Camphausen K.
Cancer. What does radiotherapy do to endothelial cells.
Science. 293: 227-8, 2001.
154)  Joussen AM, Huang S, Poulaki V, Camphausen K, Beecken WD, Kirchhof B, Adamis AP.
In vivo retinal gene expression in early diabetes.
Invest Ophthalmol Vis Sci. 42: 3047-57, 2001.
155)  Joussen AM, Huppertz B, Koch HR, Kernert N, Camphausen K, Schlosser K, Foerster AM, Kruse FE, Lappas A, Kirchhof B.
Low-dose-rate ionizing irradiation for inhibition of secondary cataract formation.
Int J Radiat Oncol Biol Phys. 49: 817-25, 2001.
156)  Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O'Reilly MS.
Radiation therapy to a primary tumor accelerates metastatic growth in mice.
Cancer Res. 61: 2207-11, 2001.
157)  Richert JR, Robinson ED, Camphausen K, Martin R, Voskuhl RR, Faerber MA, McFarland HF, Hurley CK.
Diversity of T-cell receptor V alpha, V beta, and CDR3 expression by myelin basic protein-specific human T-cell clones.
Neurology. 45: 1919-22, 1995.
158)  Richert JR, Robinson ED, Camphausen K, Hastings E, Martin R, Voskuhl R, McFarland HF.
T-cell receptor alpha and beta CDR3 expression by myelin basic protein-specific human T-cell clones.
Ann N Y Acad Sci. 756: 317-8, 1995.
159)  Voskuhl RR, Robinson ED, Segal BM, Tranquill L, Camphausen K, Albert PS, Richert JR, McFarland HF.
HLA restriction and TCR usage of T lymphocytes specific for a novel candidate autoantigen, X2 MBP, in multiple sclerosis.
J Immunol. 153: 4834-44, 1994.
160)  Bamji AN, Dieppe PA, Haslock DI, Shipley ME.
What do rheumatologists do? A pilot audit study.
Br. J. Rheumatol. 29: 295-8, 1990.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/25/2014.